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1. Introduction
Glycosuria testing at each prenatal visit continues to be
practiced in many European countries despite consensus that
glycosuria is not a valid screening test for gestational diabetes
mellitus (GDM). The American Diabetes Association recommends
the glucose challenge test (GCT) at 24–28 weeks gestational age
(GA) for the screening of GDM, and lists glycosuria as a pre-
screening clinical characteristic that may prompt glucose evalua-
tion at the first prenatal visit [1]. Yet surprisingly little is known
about this extremely common measurement. Older physiological
studies show that glycosuria occurs more frequently during
pregnancy because of reduced tubular reabsorption of filtered
glucose [2]. Studies on glycosuria are hampered by its variable but
generally low prevalence and its typically intermittent nature. In a
US cohort of >2500 gravidas, the prevalence of glycosuria rose
from 1.7% in the first two trimesters to 8.6% in the third trimester
[3]. Glycosuria was present in only 3.6% of 1001 gravidas in
Germany at 33  3 weeks GA [4].
In order to clarify the physiological and clinical relevance of
glycosuria, we decided to study glycosuria 60 min after the GCT
(which consists of a 50 g glucose load), immediately before blood
sampling. We anticipated that this would increase the glycosuria
prevalence. In addition, the plasma and urine response to a glucose
load might be compared.
2. Materials and methods
2.1. Patients
The departmental ante-partum care trajectory recommends
that a GCT should be carried out between 24 and 28weeks GA in all
pregnancies; in practice, this occurs either at our own clinic or at
the office of the family physician/private midwife involved in the
ante-partum care. For this study, we included all consecutive
women receiving a GCT at our clinic between April 1st and
September 30th, 2008. GCTs were performed regardless of time of
day or previous meals, and consisted of a 50 g oral glucose load
with no adding of lemon extract, as this might influence the
measurement [5]. The gravidas were asked not to eat, drink, smoke
or chew gum for the next hour, and to remain within the clinic
boundaries. The patients were asked to provide their routine urine
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Objective: Urine testing for glucose is commonly performed during pregnancy but little is known about
the regulation and clinical value of glycosuria because studies are hampered by its low prevalence and
intermittent nature. The aim of this study was to compare the urine and plasma response 60 min after a
50 g oral glucose challenge in the setting of gestational diabetes mellitus (GDM) screening.
Study design: Of 338 consecutively enrolled gravidas, 325 completed the study. Glycosuria was
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higher plasma glucose (p < 0.001), lower height (p = 0.004) and lower body weight throughout
pregnancy (p = 0.014); however, glycosuria was not related to age, parity, body mass index (BMI),
highest blood pressure or newborn size at birth. The sensitivity for a GDM diagnosis was 8.2%.
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responders were younger and had a lower body weight and BMI than plasma responders.
Conclusion: Glycosuria after an oral glucose challenge depends on the plasma glucose excursion, and is
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sample at the time of the blood sample (60 min after glucose load)
rather than at the time of their weight check. Clinic midwives were
informed about the purpose of the study and they checked for
glycosuria (1Combur3-Test, Roche Diagnostics, Vilvoorde, Bel-
gium) as they routinely do. The urine stick indicates no glycosuria,
1+ glycosuria (corresponding to 50 mg/dl or 2.8 mmol/l), 2+
(100 mg/dl or 5.5 mmol/l) or 3+ (300 mg/dl or 17 mmol/l). A
venous blood sample was subsequently drawn and sent to the
laboratory. Plasma glucose was measured by a colorimetric–
enzymatic method (hexokinase-glucose-6-phosphate-dehydroge-
nase, Roche application code 668) on a Hitachi/Roche-Modular P
analyzer. An abnormal GCT was defined as a plasma venous
glucose concentration of 140 mg/dl (7.8 mmol/l). A subsequent
100 g oral glucose tolerance test (OGTT) with2 abnormal plasma
glucose values according to the Carpenter–Coustan criteria
(fasting, 95 mg/dl; 1 h, 180 mg/dl; 2 h, 155 mg/dl; and 3 h,
140 mg/dl) was defined as GDM; nutritional counselling by a
dietician or/and insulin were then instituted. All clinical data
pertaining to the mother and baby were retrieved from the
patients’ notes and electronic records. Pre-pregnancy weight was
obtained at the first visit, based on the patients’ recall. Weight gain
was calculated between pre-pregnancy weight and weight
recorded at GCT, and weight gain between the recording at the
GCT and the final visit; the total weight gain was the sum.
2.2. Data analysis
We used the NCSS software, version 2004 (Kaysville, UT, USA).
Birth weight of twins was averaged. The birth weight standard
deviation (SD)-score was computed as (actual–mean) birth
weight/birth weight SD for a particular GA, with mean and SD-
values obtained from more than 429,000 births [6]. Small-for-GA
(10th percentile), appropriate-for-GA (11–90th percentile) and
large-for-GA (>90th percentile) babies were identified using the
same database. For glycosuria, the results were stratified into three
groups: no glycosuria, 1+ glycosuria, and 2–3+ glycosuria; for the
plasma glucose level, the group with a value of 140 mg/dl was
compared with the <140 mg/dl group. Continuous variables were
compared using two-sample t-tests taking account of normality
and variance (two groups) or one-way ANOVA (three groups); if
the ANOVA-test showed a p value <0.05, Bonferroni’s post hoc
multiple-comparison test was used to compare individual groups.
The x2-test was used for comparisons of categorical variables.
Multiple regression analysis was done using Huber’s method
(robust regression). Data are presented asmeans (standard error of
mean, SEM).
3. Results
From 338 consecutive women enrolled in the study, 13 women
were excluded from analysis because they did not have a complete
follow-up and delivered elsewhere. Thirteen of the 325 included
pregnancies were twin pregnancies (4%). The maternal age was
30.6 (0.3) years (range 18–49). One hundred and fifty-four (47.4%)
were nulliparous, 110 (33.9%) were primiparous, and 61 (18.8%)
were para 2. The GCT was carried out at 26.0 (0.9) weeks GA
(range 23.0–32.8); 54 (16.6%) of the tests were abnormal. Forty-six
of thesewomen (85%) underwent an OGTT, whichwas abnormal in
10 cases, translating into a 3% (10/317) incidence of GDM (Fig. 1).
All GDM women received medical nutrition therapy, and two
patients were treated with insulin as well.
Of the total group, 26.2% had a positive glycosuria testing.
Table 1 shows that positive glycosuria was not related to age or
parity, but that positive glycosuria was related to both shorter
stature and lower body weight before pregnancy and throughout
pregnancy; yet there was no relationship with the BMI. Women
with positive glycosuria tended to have a lower total gestational
weight gain, but no difference in the pre- or post-GCT weight gain
could be identified. The amount of glycosuria was also strongly
related to the GCT result; 50% of patients with 2 or 3+ glycosuria
Fig. 1. Flow diagram of the study. Urine: 0 = no glycosuria, 1+ = glycosuria to 50 mg/dl or 2.8 mmol/l,>2+ = >100 mg/dl or>5.5 mmol/l. GCT: abnormal when plasma venous
glucose concentration 140 mg/dl (7.8 mmol/l). OGTT (100 g glucose): abnormal when 2 abnormal plasma glucose values according to the Carpenter–Coustan criteria
(fasting, 95 mg/dl; 1 h, 180 mg/dl; 2 h, 155 mg/dl; and 3 h, 140 mg/dl). GDM, gestational diabetes mellitus.
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had a positive GCT. Positive glycosuria was not related to blood
pressure or the development of pre-eclampsia. Finally, positive
glycosuria was related to a lower birth weight, but not SD-score,
length or head circumference.
By contrast, Table 2 shows that gravidas with a positive GCT
were older and had a higher BMI, largely owing to a shorter stature.
Total weight gain tended to be lower in gravidas with a positive
GCT, owing to a reduced post-GCT weight gain. There was no
difference in highest recorded systolic (p = 0.90) or diastolic
(p = 0.98) blood pressure, or pre-eclampsia incidence (p = 0.11)
(data not shown). Therewas no difference in birthweight (Table 2),
length (p = 0.13) or head circumference (p = 0.23) (data not
shown).
Table 3 compares ‘‘plasma’’ responders to the GCT—i.e., a
plasma glucose value of 140 mg/dl but no glycosuria—with
‘‘urine’’ responders to the GCT—i.e., any degree of glycosuria but a
completely normal plasma glucose level (<130 mg/dl, which is the
strictest cut-off value for the GCT [1]). Plasma responders were
older and had a higher body weight and BMI through pregnancy
than urine responders, but the stature of plasma and urine
responders was not different. There was no difference in total
weight gain, or weight gain before (p = 0.72) or after (p = 0.22) the
GCT. The highest recorded systolic (p = 0.85) and diastolic
(p = 0.37) blood pressure was comparable, as was the incidence
of pre-eclampsia (p = 0.26). The birth datawere comparable aswell
(Table 3).
Table 2
Pregnancy characteristics according to the GCT result (plasma glucose measurement).
<140mg/dl (n=271) 140mg/dl (n=54) Two-sample t-test p x2-test p
GA at GCT (week) 26.0 (0.1) 25.9 (0.2) 0.57
Maternal age (year) 30.2 (0.3) 32.6 (0.8) <0.001
Height (cm) 166.3 (0.4) 164.4 (1.0) 0.059
Pre-pregnancy body weight (kg) 64.4 (0.7) 66.2 (1.6) 0.21
Pre-pregnancy BMI (kg/m2) 23.2 (0.3) 24.4 (0.5) 0.02
Body weight at GCT (kg) 72.9 (0.8) 74.4 (1.7) 0.30
Total weight gain (kg) 13.8 (0.5) 12.9 (0.7) 0.06
Weight gain before GCT (kg) 6.2 (0.8) 6.9 (1.7) 0.71
Weight gain after GCT (kg) 7.6 (0.7) 6.0 (1.6) 0.004
GA at delivery (week) 39.1 (0.1) 39.0 (0.3) 0.67
Twin pregnancy (n, %) 10 (3.7%) 3 (5.6%) 0.52
Birth weight (g) 3345 (30) 3224 (77) 0.11
Birth weight SD-score +0.19 (0.06) +0.32 (0.14) 0.18
SGA/AGA/LGA (%)a 7/77/16 8/84/8 0.35
aSGA, small-for-GA; AGA, appropriate-for-GA; and LGA, large-for-GA (analysis in singletons only).
Table 1
Pregnancy characteristics according to the degree of maternal glycosuria at the GCT.
0 (n=240) 1+ (n=59) 2 or 3+ (n=26) ANOVA p x2-test p
Maternal age (year) 30.5 (0.3) 31.4 (0.7) 29.7 (0.9) 0.27
Nulliparity (n, %) 108 (45%) 30 (51%) 16 (62%) 0.23
Height (cm) 167 (0.4) 165 (0.8) 163 (1.4)* 0.014
Pre-pregnancy body weight (kg) 65.9 (0.8) 62.5 (1.2) 58.6 (1.5)* 0.004
Pre-pregnancy BMI (kg/m2) 23.7 (0.3) 23.1 (0.5) 22.0 (0.7) 0.14
Body weight at GCT (kg) 74.1 (0.9) 71.7 (1.5) 66.7 (1.8)* 0.011
Body weight at final visit (kg) 80.1 (0.8) 77.2 (1.6) 71.9 (2.0)* 0.005
Total weight gain (kg) 14.1 (0.4) 13.2 (1.4) 10.5 (3.1) 0.089
Weight gain before GCT (kg) 6.9 (0.8) 5.4 (2.1) 3.0 (3.9) 0.31
Weight gain after GCT (kg) 7.2 (0.7) 7.8 (1.7) 7.5 (2.8) 0.93
Highest systolic blood pressure (mmHg) 127 (1) 128 (2) 126 (3) 0.75
Highest diastolic blood pressure (mmHg) 79 (0.6) 80 (1) 78 (2) 0.73
Pre-eclampsia (n, %) 8 (3.3) 2 (3.4) 2 (7.7) 0.53
GA at GCT (week) 26.0 (0.1) 25.7 (0.2) 26.5 (0.3) 0.08
Plasma glucose at GCT (mg/dl) 113 (2) 120 (4) 137 (6)** <0.001
Plasma glucose 140mg/dl (n, %) 29 (12) 12 (20) 13 (50) <0.001
Treated GDM (diet or/and insulin, %) 3 (1.3) 5 (8) 2 (8) 0.006
GA at delivery (week) 39.1 (0.1) 39.2 (0.2) 38.5 (0.4) 0.16
Twin pregnancy (n, %) 9 (3.8) 2 (3.4) 2 (7.7) 0.60
Birth weight (g) 3356 (33) 3310 (61) 3072 (99)* 0.025
Birth weight SD-score +0.21 (0.07) +0.10 (0.13) 0.09 (0.13) 0.33
Length (cm) 50.3 (0.2) 49.8 (0.3) 50.1 (0.4) 0.49
Head circumference (cm) 34.6 (0.1) 34.5 (0.2) 34.3 (0.3) 0.56
SGA/AGA/LGA (%)a 7/76/16 9/79/12 4/96/0 0.21
aSGA, small-for-GA; AGA, appropriate-for-GA; and LGA, large-for-GA (analysis in singletons only).
* A significant difference from 0 glycosuria group according to Bonferroni’s multiple-comparison test.
** A significant difference from 0 to 1+ glycosuria groups according to Bonferroni’s multiple-comparison test.
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Since we found a relationship between glycosuria and birth
weight (Table 1), this issue was further explored in a multiple
regression analysis, with birth weight as the dependent variable
and the following independent variables: maternal age, parity
(nulliparous or parous), pre-pregnancy body weight, height, total
weight gain, highest recorded diastolic blood pressure, GCT result,
glycosuria (0, 1+ or 2+), and smoking (yes or no); and GA at
delivery and newborn sex. This analysis was performed in 295
singleton pregnancies with complete data. In the regressionmodel
(F-ratio = 21.0, R2 = 0.471, p <0.001), birth weight was related to
later GA (F-ratio = 133.7, partial R2 = 0.322, p < 0.001), taller
stature (F-ratio = 18.7, partial R2 = 0.062, p < 0.001), male sex (F-
ratio = 17.1, partial R2 = 0.057, p < 0.001), no smoking (F-ra-
tio = 14.2, partial R2 = 0.048, p < 0.001), more robust weight gain
(F-ratio = 11.3, partial R2 = 0.038, p < 0.001), and higher parity (F-
ratio = 7.2, partial R2 = 0.025, p = 0.008); however, age (p = 0.22),
pre-pregnancy body weight (p = 0.18), diastolic blood pressure
(p = 0.43), post-challenge plasma glucose (p = 0.31) and post-
challenge glycosuria (p = 0.66) did not contribute to the model.
4. Comment
The novel finding of the current study is that glycosuria after a
50 g glucose load in the setting of GDM screening is related to (1)
higher plasma glucose excursion, and (2) lower body size (both
height and weight) (Table 1). A comparison of urine and plasma
responders to the glucose load reveals that urine responders have a
lower body weight and are younger than plasma responders, while
height is comparable in both groups (Table 3).
Body weight is correlated with both pre-pregnancy plasma
volume and plasma volume expansion during pregnancy [7]. Thus,
gravidas with lower body weight are expected to have a lower
plasma distribution volume. The relationship between body
weight and glomerular function is unclear because studies use
BMI rather than body weight and correct glomerular filtration rate
for height or body surface [8,9]. Nonetheless, the filtration fraction
(i.e., glomerular filtration rate/effective renal plasma flow) is lower
in healthy people with low BMI [8], suggesting that the glycosuria
in gravidas with low body weight is not the result of a more
effective filtration process.
Body weight is known to affect the kinetics of hormones and
drugs taken orally. For example, serum estradiol is higher in
estrogen-treated postmenopausal womenwith lower body weight
[10]. Also, hormone steady-state levels are reached later in obese
women starting an oral contraceptive [11].
Short stature is a more important risk factor for GDM than is
high pre-pregnancy body weight [12–15]. Lower height is also a
risk factor for impaired glucose tolerance in non-pregnant adults
[16]. Short stature is associated with insulin resistance [13,16] but
the underlying pathophysiological pathways remain to be
elucidated [15].
In this study, the plasma glucose response but not the degree of
glycosuria is related to the subject’s BMI. BMI is an index of
adiposity, and as such probably a better marker for GDM than is
body weight [12,14]; indices of abdominal adiposity (waist
circumference, waist-to-hip ratio) may be even more precise
markers [17]. However, glycosuria is related to the gravida’s body
frame and size, but not her adiposity.
A higher age is another major risk factor for GDM, and together
with increased adiposity explains the rising prevalence of glucose
intolerance during pregnancy [18,19]. As expected, glycosuria is
not associated with age.
Thus, although glycosuria depends on the plasma glucose
excursion and is more prominent in shorter gravidas, glycosuria
fails to capture the clinical risk profile of GDM. In the current study,
post-load glycosuria has a sensitivity of only 8.2% to diagnose
GDM, with only 29% (25/85) of women with glycosuria having an
abnormal GCT. This is comparable to the results of Buhling et al. [4]
who reported a sensitivity of 10.8% for pre-load glycosuria.
Since glycosuria equates energy loss, glycosuria might be a
determinant of gestational weight gain. Indeed, weight gain occurs
in diabetic subjects upon intensifying their glycemic control [20];
the disappearance of glycosuria is thought to contribute to this
weight gain [21]. In addition, women with GDM were reported to
have a lower gestational weight gain [22]. Here, we confirm that
women with a positive GCT experience a lower weight gain in the
third trimester. This may be explained in part to the institution of
nutrition therapy (in 10/54 subjects), but since the other women
did not receive such therapy, other factors must be involved. We
demonstrate a trend for a lower total weight gain in women with
2+ or 3+ glycosuria, but apparently no lower weight gain in the
third trimester when glycosuria is quantitatively more important.
Gribble et al. [3] reported that incidental glycosuria in the third
trimester is unrelated to gestational weight gain. In sum, the
available data are not definitive and further studies are needed in
larger samples.
We document no relationship of post-load glycosuria with the
highest recorded systolic or diastolic blood pressure, or the
incidence of pre-eclampsia. Buhling et al. [4] reported a higher
diastolic but not systolic blood pressure in glycosuria-positive
Table 3
Comparison between ‘‘plasma’’ and ‘‘urine’’ responders to a GCT.
Plasma glucose 140mg/dl
but no glycosuria (n=29)
Plasma glucose <130mg/dl
but glycosuria 1, 2 or 3+ (n=50)
Two-sample
t-test p
x2-test p
GA at GCT (week) 25.8 (0.3) 25.9 (0.2) 0.93
Plasma glucose at GCT (mg/dl) 156 (3) 104 (2) <0.001
Maternal age (year) 33.9 (1.0) 30.9 (0.7) 0.036
Height (cm) 166.1 (1.3) 165.3 (0.9) 0.89
Pre-pregnancy body weight (kg) 70.8 (2.2) 61.1 (1.3) <0.001
Pre-pregnancy BMI (kg/m2) 25.8 (0.7) 22.5 (0.5) <0.001
Body weight at GCT (kg) 79.1 (2.3) 70.0 (1.6) 0.002
Body weight at final visit (kg) 83.9 (2.5) 76.0 (1.8) 0.006
Total weight gain (kg) 13.2 (1.0) 11.6 (2.2) 0.50
GA at delivery (week) 39.0 (0.4) 39.1 (0.2) 0.89
Twin pregnancy (n, %) 2 (6.9) 2 (4) 0.57
Birth weight (g) 3257 (105) 3255 (63) 0.99
Birth weight SD-score +0.05 (0.21) +0.02 (0.13) 0.55
SGA/AGA/LGA (%)a 11/78/11 8/83/8 0.84
aSGA, small-for-GA; AGA, appropriate-for-GA; LGA, large-for-GA (analysis in singletons only).
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women. The discrepancy might be explained by the fact that the
latter study examined pre-load glycosuria at about 34 weeks GA,
which may reflect insulin resistance to a greater degree than post-
load glycosuria at 24–28 weeks GA. The association between
insulin resistance and hypertension during pregnancy is well
established [23].
Birth weight is slightly lower in pregnancies with 2+ or 3+
glycosuria, but without differences in other size measurements. In
addition, neither the urine nor the plasma post-load response is a
significant predictor of birth weight in a multiple regression. The
plasma result might seem surprising in view of the linear
relationship between the maternal fasting or post-load plasma
glucose level and the risk of a large-for-GA baby, as shown
definitively in the HAPO study [24]. However, the HAPO subject
sample was very large (>25,000), while our findings in a much
smaller sample would indicate that other factors are more
important. Indeed, we replicate a similar finding from a previous
studyatour centre [25]andfindings fromother studies [26,27]. Even
in women with GDM, maternal obesity is a more important risk
factor for macrosomia than is the severity of hyperglycemia [28].
This study has limitations and strengths. While ethnic back-
ground was not recorded, our clinic serves a diverse population
comparable to other series [18]. Pre-pregnancy weight was self-
reported at the first antenatal visit. Systematic reviews have
concluded that women tend to underreport their weight [29,30];
however, we also recorded weight at the GCT and at the final visit.
Glycosuria testingwas performed by clinic nurses, but urine glucose
testing is a routine practice at our clinic. Finally, the follow-up of an
abnormal GCT (oral glucose tolerance test, GDMmanagement) was
the responsibility of the treating obstetrician. The strength of the
current study is that it is the first study to compare the plasma and
urine response to an oral glucose load at the same time.
In conclusion, glycosuria after a glucose challenge test during
pregnancy depends on the plasma glucose excursion and is more
pronounced in womenwith smaller body size (height and weight).
Glycosuria is not related to age, parity or BMI (adiposity). In
addition, glycosuria is a poor predictor of pregnancy outcome
including GDM, pre-eclampsia and newborn size at birth.
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